BioMarin Secures $850M in Senior Notes to Fund Amicus Acquisition
Event summary
- BioMarin closed an $850M offering of 5.500% senior unsecured notes due 2034.
- Proceeds, along with $2.8B in new term loans and cash, will fund the Amicus acquisition.
- Notes are guaranteed by BioMarin subsidiaries and Amicus post-acquisition.
- Funds are held in escrow pending deal completion by December 19, 2026.
- Notes include customary covenants restricting debt, dividends, and asset disposals.
The big picture
BioMarin's $850M senior notes offering is a strategic move to finance its acquisition of Amicus, a deal that would expand its rare disease portfolio. The biotech sector has seen increased M&A activity as companies seek to bolster pipelines amid competitive pressures. BioMarin's ability to manage this debt load will be critical as it integrates Amicus and maintains its focus on genetically defined conditions.
What we're watching
- Execution Risk
- Whether BioMarin can complete the Amicus acquisition by the December 2026 deadline to avoid redeeming the notes.
- Debt Management
- How BioMarin will balance the new debt obligations with operational cash flow post-acquisition.
- Strategic Integration
- The pace at which BioMarin can integrate Amicus's operations and pipeline to justify the acquisition cost.
Related topics